Alcon
- Home ›
- CH ›
- Healthcare
Alcon, Inc. develops and manufactures eye care products for eye care professionals and their patients. The last earnings update was 89 days ago. More info.
Add to Portfolio Compare Print
ALC Share Price and Events
7 Day Returns
1 Year Returns
ALC Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Alcon (ALC) | -0.5% | -3.3% | - | - | - | - |
| CH Medical Equipment | 1.5% | 1.3% | 12.1% | 23.4% | 86.3% | 126.3% |
| CH Market | 1.3% | 2.9% | 3.1% | 9.8% | 18.7% | 13.6% |
1 Year Return vs Industry and Market
- No trading data on ALC.
- No trading data on ALC.
Price Volatility
Related Companies
Value
Is Alcon undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Alcon
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Alcon.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 19 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.7% |
| Perpetual Growth Rate | 10-Year CH Government Bond Rate | 3.3% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year CH Govt Bond Rate | 3.3% |
| Equity Risk Premium | S&P Global | 6% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.85 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 21%) (0.71%)) |
0.904 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.9 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (0.904 * 5.96%) |
8.66% |
Discounted Cash Flow Calculation for SWX:ALC using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Alcon is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 8.66%) |
|
|---|---|---|---|
| 2019 | 646.18 | Analyst x6 | 594.67 |
| 2020 | 803.50 | Analyst x11 | 680.50 |
| 2021 | 1,093.32 | Analyst x11 | 852.14 |
| 2022 | 1,270.00 | Analyst x5 | 910.94 |
| 2023 | 1,525.00 | Analyst x4 | 1,006.65 |
| 2024 | 1,734.90 | Est @ 13.76% | 1,053.91 |
| 2025 | 1,919.09 | Est @ 10.62% | 1,072.87 |
| 2026 | 2,080.58 | Est @ 8.41% | 1,070.42 |
| 2027 | 2,223.57 | Est @ 6.87% | 1,052.79 |
| 2028 | 2,352.39 | Est @ 5.79% | 1,025.00 |
| Present value of next 10 years cash flows | $9,319.89 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $2,352.39 × (1 + 3.28%) ÷ (8.66% – 3.28%) |
$45,096.21 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $45,096.21 ÷ (1 + 8.66%)10 |
$19,649.65 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $9,319.89 + $19,649.65 |
$28,969.54 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $28,969.54 / 488.70 |
$59.28 |
| Calculation | Result | |
|---|---|---|
| Exchange Rate | USD/CHF
(Reporting currency to currency of SWX:ALC) |
0.996 |
| Value per Share (CHF) |
= Value per Share in USD x Exchange Rate (USD/CHF)
= $59.28 x 0.996 |
CHF59.04 |
| Value per share (CHF) | From above. | CHF59.04 |
| Current discount | Discount to share price of
CHF58.46
= -1 x (CHF58.46 - CHF59.04) / CHF59.04 |
1% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Alcon's share price is below the future cash flow value, but not at a moderate discount (< 20%).
- Alcon's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Alcon's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Alcon's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in USD | Not available |
| SWX:ALC Share Price ** | SWX (2019-06-19) in CHF | CHF58.46 |
| SWX:ALC Share Price converted to USD reporting currency | Exchange rate (CHF/ USD) 1.004 | $58.69 |
| Switzerland Medical Equipment Industry PE Ratio | Median Figure of 6 Publicly-Listed Medical Equipment Companies | 31.18x |
| Switzerland Market PE Ratio | Median Figure of 174 Publicly-Listed Companies | 18.47x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Alcon.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to compare the PE ratio to the industry average as no data exists.
- Unable to calculate PE ratio for Alcon, we can't compare the value of its earnings to the Switzerland market.
Price based on expected Growth
Does
Alcon's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 0x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts |
62.4%per year |
| Europe Medical Equipment Industry PEG Ratio | Median Figure of 40 Publicly-Listed Medical Equipment Companies | 2.37x |
| Switzerland Market PEG Ratio | Median Figure of 125 Publicly-Listed Companies | 2.19x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Alcon, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Alcon's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in USD | Not available |
| SWX:ALC Share Price * | SWX (2019-06-19) in CHF | CHF58.46 |
| SWX:ALC Share Price converted to USD reporting currency | Exchange rate (CHF/ USD) 1.004 | $58.69 |
| Switzerland Medical Equipment Industry PB Ratio | Median Figure of 6 Publicly-Listed Medical Equipment Companies | 3.56x |
| Switzerland Market PB Ratio | Median Figure of 215 Publicly-Listed Companies | 1.68x |
* Primary Listing of Alcon.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to compare the PB ratio to the industry average as no data exists.
Value checks
We assess Alcon's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Alcon has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Alcon expected to perform in the next 1 to 3 years based on estimates from 19 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Alcon's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
- Alcon's earnings growth is expected to exceed the Switzerland market average.
- Alcon's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| SWX:ALC Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 19 Analysts | 62.4% |
| SWX:ALC Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 19 Analysts | 5.2% |
| Switzerland Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 36.1% |
| Switzerland Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 7.2% |
| Switzerland Market Earnings Growth Rate | Market Cap Weighted Average | 10.9% |
| Switzerland Market Revenue Growth Rate | Market Cap Weighted Average | 3.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (5 months ago) | See Below |
| Future Estimates | Average of up to 19 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 9,055 | 1,880 | 864 | 6 |
| 2022-12-31 | 8,594 | 1,745 | 671 | 7 |
| 2021-12-31 | 8,123 | 1,651 | 521 | 17 |
| 2020-12-31 | 7,712 | 1,373 | 105 | 19 |
| 2019-12-31 | 7,352 | 1,214 | -93 | 19 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 7,153 | 1,140 | -227 |
| 2018-09-30 | 7,123 | 1,375 | 175 |
| 2017-12-31 | 6,792 | 1,218 | 256 |
| 2016-12-31 | 6,596 | 1,245 | -170 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (5 months ago) | See Below |
| Future Estimates | Average of up to 19 Analyst Estimates (S&P Global) | See Below |
All data from Alcon Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 0.74 | 0.74 | 0.74 | 1.00 |
| 2022-12-31 | 0.56 | 0.56 | 0.56 | 1.00 |
| 2021-12-31 | 0.87 | 1.67 | 0.35 | 6.00 |
| 2020-12-31 | 0.29 | 0.45 | 0.12 | 6.00 |
| 2019-12-31 | -0.25 | -0.13 | -0.42 | 6.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-12-31 | |
| 2018-09-30 | |
| 2017-12-31 | |
| 2016-12-31 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Alcon's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Alcon has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Alcon performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Alcon does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
- Unable to compare Alcon's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Alcon's 1-year growth to the CH Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Alcon Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 7,153.00 | -227.00 | 2,790.00 | 585.00 |
| 2018-09-30 | 7,123.00 | 175.00 | 2,725.00 | 527.00 |
| 2017-12-31 | 6,792.00 | 256.00 | 2,596.00 | 545.00 |
| 2016-12-31 | 6,596.00 | -170.00 | 2,526.00 | 481.00 |
| 2015-12-31 | 6,776.00 | 308.00 | 2,337.00 | 457.00 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Alcon has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Alcon has efficiently used its assets last year compared to the CH Medical Equipment industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Alcon improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Alcon's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Alcon has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Alcon's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Alcon's finances.
The net worth of a company is the difference between its assets and liabilities.
- Alcon is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Alcon's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 16.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Alcon Company Filings, last reported 5 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 22,639.00 | 203.00 | 227.00 |
| 2018-09-30 | 22,282.00 | 202.00 | 139.00 |
| 2017-12-31 | 23,029.00 | 195.00 | 172.00 |
| 2016-12-31 | 23,012.00 | 275.00 | 162.00 |
| 2015-12-31 | 23,637.00 | 302.00 | 285.00 |
- Alcon's level of debt (0.9%) compared to net worth is satisfactory (less than 40%).
- Unable to establish if Alcon's debt level has increased without past 5-year debt data.
- Debt is well covered by operating cash flow (561.6%, greater than 20% of total debt).
- Alcon is making a loss, therefore interest payments are not well covered by earnings.
Financial health checks
We assess Alcon's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Alcon has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Alcon's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
CHF2,000 of
Alcon
shares you are expected to receive
CHF0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Alcon's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Alcon's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 19 Analyst Estimates (S&P Global) | See Below |
| Switzerland Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 5 Stocks | 1% |
| Switzerland Market Average Dividend Yield | Market Cap Weighted Average of 166 Stocks | 3% |
| Switzerland Minimum Threshold Dividend Yield | 10th Percentile | 1.2% |
| Switzerland Bottom 25% Dividend Yield | 25th Percentile | 2% |
| Switzerland Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | 0.28 | 2.00 |
| 2021-12-31 | 0.24 | 7.00 |
| 2020-12-31 | 0.21 | 8.00 |
| 2019-12-31 | 0.19 | 5.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Alcon has not reported any payouts.
- Unable to verify if Alcon's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Alcon's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Alcon afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Alcon has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| AGE | 53 |
| TENURE AS CEO | 0.9 years |
CEO Bio
Mr. David J. Endicott had been the Chief Executive Officer of Alcon at Novartis AG since July 1, 2018 until April 2019. Mr. Endicott has been the President of Hospira Medical Devices at Hospira Inc. since March 10, 2014. Mr. Endicott served as a Corporate Vice President and President of Allergan Medical, Asia Pacific and Latin America at Allergan Inc. since April 2011. He served as Corporate Vice President and President of Allergan Medical at Allergan, Inc. since August 2010. He served as Corporate Vice President and President of Europe, Africa and Middle East at Allergan, Inc. from October 2004 to August 2010 and managed the expansion of Allergan's business internationally, including Allergan's entry into new markets such as Turkey and Poland. He served as Senior Vice President of U.S. Specialty Pharmaceuticals from January 2004 to October 2004, Vice President and General Manager of Canada from February 2000 to December 2003 and Vice President of U.S. Managed Markets since 1998. He served as a Director of ZELTIQ Aesthetics, Inc. since April 25, 2016 until April 28, 2017. He served various roles at Allergan since joining Allergan Medical in 1986. He served as a Director of Orexigen Therapeutics, Inc. since November 30, 2012 until July 27, 2018. Mr. Endicott earned his Bachelor's Degree in Chemistry from Whitman College, his Master's in Business Administration from the University of Southern California and is a Graduate of the Harvard Business School Advanced Management Program.
CEO Compensation
- Insufficient data for David to compare compensation growth.
- Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in Switzerland.
Management Team Tenure
Average tenure and age of the Alcon management team in years:
- The tenure for the Alcon management team is about average.
Management Team
Merrick McCracken
Senior Vice President of Human Resources
$2M
Ed McGough
Senior Vice President of Global Manufacturing and Technical Operations
$2M
57
David Endicott
Chief Executive Officer
53
0.9 yrs
David Murray
Chief Financial Officer
3.8 yrs
Allen Baker
Chief Operating Officer and Executive Vice President
Sue-Jean Lin
Senior VP & Chief Information Officer
Karen King
Senior VP and Head of Global Investor Relations & Communications
Royce Bedward
Senior VP & General Counsel
52
Bettina Maunz
Global Head of Communications and Vice President
Sergio Duplan
Region President for North America
3.8 yrs
Board of Directors Tenure
Average tenure and age of the Alcon board of directors in years:
- The tenure for the Alcon board of directors is about average.
Board of Directors
Dan Vasella
Chairman
$169K
65
8.7 yrs
Cary Rayment
Vice Chairman
$290K
70
Thomas Plaskett
Director
74
16.1 yrs
Kevin Buehler
Director
$9M
60
10.1 yrs
Joan Miller
Independent Director
59
10.1 yrs
Paul Choffat
Director
68
8.8 yrs
Enrico Vanni
Director
67
8.8 yrs
Urs Baerlocher
Director
75
8.8 yrs
Norman Walker
Director
65
8.8 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CHF) | Value (CHF) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Alcon's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Alcon has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
Company Info
Description
Alcon, Inc. develops and manufactures eye care products for eye care professionals and their patients. It offers surgical products, which include technologies and devices for cataract, retinal, glaucoma, and refractive surgery; advanced technology intraocular lenses to treat cataracts and refractive errors, such as presbyopia and astigmatism; and advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery. The company also provides pharmaceutical products for elevated intraocular pressure caused by glaucoma; anti-inflammatories; anti-infective to aid in the treatment of bacterial infections and bacterial conjunctivitis; ophthalmic solutions to treat inflammation and pain associated with ocular surgery; eye inflammation and infection solutions following cataract surgery; and vitreomacular adhesion, eye and nasal allergy treatment solutions, and over-the-counter dry eye relief and ocular vitamins. In addition, it offers vision care products, such as contact lenses and lens care products; daily disposable, monthly replacement, and color-enhancing contact lenses for comfortable and convenient vision correction options; contact lens care products; multi-purpose and hydrogen-peroxide based solutions to clean, rinse, and disinfect contact lenses; rewetting drops; and daily protein removers that removes protein deposits from lenses. Alcon, Inc. was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. The company was founded in 1945 and is based in Fort Worth, Texas. Alcon, Inc. was previously operating as a subsidiary of Novartis AG. Alcon, Inc.(SWX:ALC) operates independently of Novartis AG as of April 9, 2019.
Details
| Name: | Alcon, Inc. |
| ALC | |
| Exchange: | SWX |
| Founded: | 1945 |
| CHF28,569,402,000 | |
| 488,700,000 | |
| Website: | http://www.alcon.com |
| Address: |
Alcon, Inc. 6201 South Freeway, Fort Worth, Texas, 76134-2001, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| SWX | ALC | Common Shares | SIX Swiss Exchange | CH | CHF | 09. Apr 2019 | |
| NYSE | ALC | Common Shares | New York Stock Exchange | US | USD | 09. Apr 2019 | |
| DB | 2U3 | Common Shares | Deutsche Boerse AG | DE | EUR | 09. Apr 2019 | |
| BST | 2U3 | Common Shares | Boerse-Stuttgart | DE | EUR | 09. Apr 2019 | |
| LSE | 0A0D | Common Shares | London Stock Exchange | GB | USD | 09. Apr 2019 | |
| BIT | ALC | Common Shares | Borsa Italiana | IT | EUR | 09. Apr 2019 | |
| BMV | ALC N | Common Shares | Bolsa Mexicana de Valores | MX | MXN | 09. Apr 2019 | |
| BATS-CHIXE | ALCZ | Common Shares | BATS 'Chi-X Europe' | GB | CHF | 09. Apr 2019 |
Number of employees
Current staff
Industry
| Health Care Supplies | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/19 22:42 |
| End of day share price update: | 2019/06/19 00:00 |
| Last estimates confirmation: | 2019/06/14 |
| Last earnings filing: | 2019/03/22 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
